BIOMARIN PHARMACEUTICAL INC

BMRN 10-K · FY 2025
API behind this page

BMRN FY 2025 request

Playground key active
Request URL /api/financials?ticker=BMRN&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 3,221,253 2,853,915 +12.9%
Show Product Lines breakouts
ALDURAZYME 208,508 183,887 +13.4%
ALDURAZYME · Sales Channel Through Intermediary 208,508 183,887 +13.4%
BRINEURA 186,397 169,083 +10.2%
KUVAN 99,530 120,902 -17.7%
NAGLAZYME 485,400 479,584 +1.2%
PALYNZIQ 433,310 355,047 +22.0%
Product 3,167,759 2,809,445 +12.8%
Products excluding ALDURAZYME · Europe 874,331 829,031 +5.5%
Products excluding ALDURAZYME · Latin America 435,478 378,084 +15.2%
Products excluding ALDURAZYME · Rest of world 544,469 493,633 +10.3%
Products excluding ALDURAZYME · Sales Channel Directly To Consumer 2,959,251 2,625,558 +12.7%
Products excluding ALDURAZYME · US 1,104,973 924,810 +19.5%
ROCTAVIAN 35,640 26,066 +36.7%
Royalty and other revenues 53,494 44,470 +20.3%
VIMIZIM 792,051 739,784 +7.1%
VOXZOGO 926,923 735,092 +26.1%
Show Business Segments breakouts
Reportable Segment 3,221,253 2,853,915 +12.9%
Cost of Revenue 717,442 580,235 +23.6%
Show Business Segments breakouts
Reportable Segment 717,442 580,235 +23.6%
Research & Development 921,930 747,184 +23.4%
Show Product Lines breakouts
Later-stage clinical programs · Reportable Segment 308,334 27,581 +1017.9%
Marketed products · Reportable Segment 229,891 285,580 -19.5%
Research and early pipeline · Reportable Segment 383,705 434,023 -11.6%
Selling, General & Administrative 1,153,017 1,009,025 +14.3%
Amortization Of Intangible Assets 19,386 43,257 -55.2%
Total Costs & Expenses 2,811,775 2,369,701 +18.7%
Operating Income 409,478 484,214 -15.4%
Interest Income 74,904 74,883 0.0%
Interest Expense -10,899 -12,666 +14.0%
Other Operating Income Expense Net 8,997 -4,668 +292.7%
Income Before Taxes 482,480 541,763 -10.9%
Income Tax Expense (Benefit) 133,579 114,904 +16.3%
Net Income 348,901 426,859 -18.3%
Show Business Segments breakouts
Reportable Segment 348,901 426,859 -18.3%
Show Equity Components breakouts
Retained Earnings 348,901 426,859 -18.3%
EPS (Basic) 1.82 2.25 -19.1%
EPS (Diluted) 1.8 2.21 -18.6%
Wtd Avg Shares (Basic) 191,787 190,027 +0.9%
Wtd Avg Shares (Diluted) 197,394 196,708 +0.3%
Sales & Marketing (FY) — — —
Show Business Segments breakouts
Reportable Segment 530,156 476,739 +11.2%
General & Administrative (FY) — — —
Show Business Segments breakouts
Reportable Segment 622,861 532,286 +17.0%
Comprehensive Income 273,775 517,300 -47.1%
Other Comprehensive Income -75,126 90,441 -183.1%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -77,068 89,482 -186.1%
Accumulated Net Unrealized Investment Gain Loss 1,942 959 +102.5%
Accumulated Other Comprehensive Income -75,126 90,441 -183.1%
Foreign Currency Transaction Gain Loss Before Tax 6.1 8.6 -29.1%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax -92,542 104,354 -188.7%
Interest Expense (FY) — — —
Show Long-Term Debt Type breakouts
Convertible Debt 9,549 12,730 -25.0%
Net Income Loss Available To Common Stockholders Basic 348,901 426,859 -18.3%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 1,311,679 942,842 +39.1%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 895,919 613,223 +46.1%
Fair Value Inputs Level2 · Money Market Funds 895,919 613,223 +46.1%
Available For Sale Securities Debt Securities Current 248,930 194,864 +27.7%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 248,930 194,864 +27.7%
Fair Value Inputs Level2 · Asset Backed Securities 249 25,864 -99.0%
Fair Value Inputs Level2 · Corporate Debt Securities 189,566 168,104 +12.8%
Fair Value Inputs Level2 · US Government Agencies Debt Securities 59,115 896 +6497.7%
Accounts Receivable 908,214 660,535 +37.5%
Show Major Customers breakouts
Customer 148 96.8 +52.9%
Inventory 1,298,883 1,232,653 +5.4%
Other Assets Current 185,784 201,533 -7.8%
Total Current Assets 3,953,490 3,232,427 +22.3%
Non-Current Assets
Available For Sale Securities Debt Securities Noncurrent 492,242 521,238 -5.6%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 492,242 521,238 -5.6%
Fair Value Inputs Level2 · Asset Backed Securities 57,854 112,663 -48.6%
Fair Value Inputs Level2 · Corporate Debt Securities 286,289 337,118 -15.1%
Fair Value Inputs Level2 · US Government Agencies Debt Securities 148,099 71,457 +107.3%
Property, Plant & Equipment 952,508 1,043,041 -8.7%
Intangible Assets Net Excluding Goodwill 213,837 255,278 -16.2%
Goodwill 196,199 196,199 0.0%
Deferred Tax Assets 1,508,697 1,489,366 +1.3%
Other Non-Current Assets 277,049 251,391 +10.2%
Total Assets 7,594,022 6,988,940 +8.7%
Operating Lease Right-of-Use Assets 35,243 28,680 +22.9%
Intangible Assets 213,837 255,278 -16.2%
Show Finite Lived Intangible Assets By Major Class breakouts
Acquired intellectual property 127,163 — —
License payments 3,277 — —
Technology transfer 83,397 — —
Current Liabilities
Accounts Payable And Accrued Liabilities Current 759,031 606,988 +25.0%
Total Current Liabilities 759,031 606,988 +25.0%
Non-Current Liabilities
Convertible Debt Noncurrent 597,176 595,138 +0.3%
Other Non-Current Liabilities 150,816 128,824 +17.1%
Total Liabilities 1,507,023 1,330,950 +13.2%
Operating Lease Liabilities 36,576 30,501 +19.9%
Stockholders' Equity
Common Stock 192 191 +0.5%
Additional Paid In Capital Common Stock 5,956,582 5,802,068 +2.7%
Common Stock Issued Employee Stock Trust -10,508 -11,227 +6.4%
Accumulated Other Comprehensive Income -13,473 61,653 -121.9%
Retained Earnings 154,206 -194,695 +179.2%
Total Stockholders' Equity 6,086,999 5,657,990 +7.6%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -17,244 59,824 -128.8%
Accumulated Net Unrealized Investment Gain Loss 3,771 1,829 +106.2%
Accumulated Other Comprehensive Income -13,473 61,653 -121.9%
Additional Paid In Capital 5,956,582 5,802,068 +2.7%
Common Stock 192 191 +0.5%
Deferred Compensation Share Based Payments -10,508 -11,227 +6.4%
Retained Earnings 154,206 -194,695 +179.2%
Total Liabilities & Equity 7,594,022 6,988,940 +8.7%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 79,557 96,426 -17.5%
Amortization Of Financing Costs And Discounts 2,622 3,359 -21.9%
Accretion Amortization Of Discounts And Premiums Investments -4,801 -8,345 +42.5%
Stock-Based Compensation 181,409 201,571 -10.0%
Asset Impairment Charges 125,012 19,889 +528.5%
Show Restructuring Plan breakouts
Discontinuation of ROCTAVIAN 118,522 — —
Inventory Write Down 119,208 — —
Show Restructuring Plan breakouts
Discontinuation of ROCTAVIAN 119,208 — —
Deferred Income Taxes 48,738 56,096 -13.1%
Foreign Currency Transaction Gain Loss Unrealized 4,459 -16,753 +126.6%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 220,963 — —
Show Asset Acquisition breakouts
Inozyme Pharma Inc 221 — —
Other Non-Cash Items -4,414 20,135 -121.9%
Change in Accounts Receivable -228,054 -57,909 -293.8%
Change in Inventory -116,929 -63,530 -84.1%
Increase Decrease In Other Current Assets 8,891 -3,778 +335.3%
Increase Decrease In Other Noncurrent Assets -38,573 -73,700 +47.7%
Increase Decrease In Accounts Payable And Accrued Liabilities 66,136 -32,240 +305.1%
Increase Decrease In Other Operating Liabilities 14,869 14,761 +0.7%
Net Cash from Operations 827,994 572,841 +44.5%
Investing Activities
Capital Expenditures -103,038 -85,424 -20.6%
Proceeds From Sale Maturity And Collections Of Investments 337,801 633,018 -46.6%
Payments To Acquire Investments -355,875 -410,250 +13.3%
Payments To Acquire Intangible Assets -7,937 -11,994 +33.8%
Payments For Asset Acquisitions Net Of Cash Acquired -285,193 — —
Net Cash from Investing -414,242 136,491 -403.5%
Capital Expenditures Incurred But Not Yet Paid Fixed Assets 3,780 3,751 +0.8%
Capital Expenditures Incurred But Not Yet Paid Intangible Assets 1,247 6,327 -80.3%
Financing Activities
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 14,460 49,277 -70.7%
Tax Withholding for Share Compensation -55,965 -77,560 +27.8%
Proceeds From Payments For Other Financing Activities -889 -3,177 +72.0%
Net Cash from Financing -42,394 -526,447 +91.9%
Amortization of Financing Costs (FY) — — —
Show Long-Term Debt Type breakouts
Convertible Debt 107 391 -72.6%
Supplemental
Interest Paid 7,245 10,361 -30.1%
Income Taxes Paid 96,205 57,269 +68.0%
Income Taxes Paid 96,205 — —
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -2,521 4,830 -152.2%
Net Change in Cash 368,837 187,715 +96.5%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,311,679 942,842 +39.1%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key